Loading...

AstraZeneca PLC

ZEG.DEXETRA
Healthcare
Drug Manufacturers - General
160.70
0.95(0.59%)
German Market opens in 7h 48m

AstraZeneca PLC (ZEG.DE) Stock Competitors & Peer Comparison

See (ZEG.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ZEG.DE€160.70+0.59%249.2B28.49€5.64+1.69%
LLY.DE€796.00-0.45%752.1B40.47€19.67+0.68%
JNJ.DE€201.65-1.20%485.7B21.38€9.43+2.21%
4AB.DE€174.15-2.71%308B86.21€2.02+3.28%
6MK.DE€102.08-1.66%252.4B16.36€6.24+2.78%
AMG.DE€296.85-1.13%160B24.29€12.22+2.78%
GIS.DE€117.26-2.02%145.5B20.22€5.80+2.34%
PFE.F€22.93-0.43%130.7B19.81€1.16+6.40%
PFE.DE€22.93-0.43%130.4B19.76€1.16+6.40%
BRM.DE€49.41-1.18%100.6B16.69€2.96+4.34%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ZEG.DE vs LLY.DE Comparison April 2026

ZEG.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZEG.DE stands at 249.2B. In comparison, LLY.DE has a market cap of 752.1B. Regarding current trading prices, ZEG.DE is priced at €160.70, while LLY.DE trades at €796.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZEG.DE currently has a P/E ratio of 28.49, whereas LLY.DE's P/E ratio is 40.47. In terms of profitability, ZEG.DE's ROE is +0.23%, compared to LLY.DE's ROE of +0.98%. Regarding short-term risk, ZEG.DE is more volatile compared to LLY.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZEG.DE.Check LLY.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions